CA1263653A — Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
Assigned to Boehringer Ingelheim GmbH · Expires 1989-12-05 · 36y expired
What this patent protects
Abstract This invention relates to Compounds of general formula I (I) [wherein R1 represents a hydrogen atom, an alkyl group containing 1 to 6 carbon atoms, an alkenyl or alkynyl group each containing 3 to 6 carbon atoms or an alkanoyl group containin…
USPTO Abstract
Abstract This invention relates to Compounds of general formula I (I) [wherein R1 represents a hydrogen atom, an alkyl group containing 1 to 6 carbon atoms, an alkenyl or alkynyl group each containing 3 to 6 carbon atoms or an alkanoyl group containing 1 to 6 carbon atoms or represents a phenylalkyl or phenylalkanoyl group each containing 1 to 3 carbon atoms in the alkyl part (in which the phenyl nuclei may be substituted by 1 or 2 halogen atoms); R2 represents a hydrogen atom or an alkyl group containing 1 to 4 carbon atoms; and R3 represents a hydrogen atom, an alkyl group containing 1 to 7 carbon atoms, a cycloalkyl group containing 3 to 7 carbon atoms, an alkenyl or alkynyl group each containing 3 to 6 carbon atoms or an alkanoyl group containing 1 to 7 carbon atoms or represents a phenylalkyl or phenylalkanoyl group each containing 1 to 3 carbon atoms in the alkyl part (in which the phenyl nuclei may be substituted by 1 or more fluorine, chlorine or bromine atoms), and R4 represents a hydrogen atom, an alkyl group containing 1 to 4 carbon atoms or an alkenyl or alkynyl group each containing 3 to 6 carbon atoms, or R3 and R4 together with the nitrogen atom between them represent a pyrrolidino, piperidino, hexamethyleneimino or morpholino group] and acid addition salts thereof. The compounds of general formula I above in which one of the groups R1 or R3 or both groups R1 and R3 represent an acyl group are useful intermediate products for preparing the other compounds of general formula I which have interesting pharmacological properties, particularly an effect on the central nervous system and/or the circulation. The new compounds may be prepared using methods known per se.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.